Slingshot Insights | Ipci Overview

IPCI Overview

Upcoming Projects (IPCI)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (IPCI)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (IPCI)

PDUFA date for Intellipharmaceutics' (IPCI) Rexista in Pain relief due August 28, 2019
Ticker: IPCI
Occurred on: Jul 24, 2019
FDA PDUFA date for IntelliPharmaCeutics (IPCI) Rexista, an abuse-deterrent of oxycodone, set for September 25th
Ticker: IPCI
Occurred on: Sep 25, 2017
Purdue Pharma Begins Patent Infringement Case Against Intellipharmaceutics (IPCI) Regarding Abuse-Deterrent Extended-Release Oxycodone Rexista
Tickers: IPCI, Purdue Pharma
Occurred on: Apr 10, 2017
FDA Approves Metformin Intellipharmaceutics' (IPCI) Generic Form of Bristol-Myers Squibb's (BMY) Type 2 Diabetes Med Glucophage XR
Tickers: IPCI, BMY
Occurred on: Feb 25, 2017
Intellipharmaceutics International's (IPCI) Paradoxical OverDose Resistance Activating System (PODRAS) Granted Patents in U.S and Canada
Ticker: IPCI
Occurred on: Dec 21, 2016
FDA Grants Tentative Approval to Intellipharmaceutics' (IPCI) Seroquel XR for Schizophrenia and Maniac/Mixed Episodes Associated with Bipolar Disorder
Ticker: IPCI
Occurred on: Oct 07, 2016
Having now demonstrated bioequivalence for its Rexista Oxycodone XR product, Intellipharmaceutics intends to file a New Drug Application within the next 6 months
Ticker: IPCI
Occurred on: Jul 05, 2016

Strategic Initiatives (IPCI)

Don’t see a strategic initiative related to the company you care about? Create your own!